HONG KONG — The findings of a new study of gene regulation by androgen receptor (AR) splice variants (AR-Vs) by U.S and Chinese scientists could provide a pivotal pathway for drug designers to target, in order to disrupt AR-V signaling as a novel strategy for the effective treatment of advanced prostate cancer.